Literature DB >> 26823804

Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity.

Sheng-Qiang Gao1, Li-Dong Huang1, Rui-Jie Dai1, Dong-Dong Chen1, Wei-Jian Hu1, Yun-Feng Shan1.   

Abstract

Peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR) have recently been proposed as prognostic markers in ulcerative colitis. In some previous serological markers are commonly used to detect the severity of the Crohn's disease (CD), but their sensitivity and specificity are relatively low. So we want to use simple indicators which are easy to obtain to predict disease severity. Now, we investigated and compared the capacity of NLR and other inflammatory markers in detecting CD activity and differentiating CD patients from healthy controls. These CD patients had not received corticosteroid or immunosuppressive drugs within a defined period of time. Data from our hospital between 2010 and 2012 was used. Neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cells (WBC), platelet count and albumin were measured in 44 patients with active CD, 66 patients with inactive CD, and 55 healthy blood donors. Disease activity was assessed by the Crohn's Disease Activity Index. In the active CD group, NLR values were found to be elevated compared to inactive CD patients and controls (6.00±7.38, 5.53±6.18 and 1.84±0.85, respectively), but statistical difference was not found between active and inactive CD groups. The overall accuracy of NLR (cutoff: 2.13 fl), CRP (cutoff: 10.5 mg/dl), ESR (cutoff: 19.5 mm/hour) and WBC (cutoff: 9.2 × 10(9)/l) in differentiating CD patients from healthy controls was 80.9%, 67.3%, 71% and 60% respectively. NLR values were found to be correlated with WBC and CRP levels. NLR increased in CD patients compared with healthy subjects. NLR had the best accuracy in determination of CD patients and healthy controls. NLR did not show a discriminative value in disease activity.

Entities:  

Keywords:  Crohn’s disease; neutrophil-lymphocyte ratio; noninvasive monitoring

Mesh:

Substances:

Year:  2015        PMID: 26823804      PMCID: PMC4713590     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

1.  Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.

Authors:  W J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; B Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; A R Zinsmeister; S R Targan
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

2.  C-reactive protein reassessed.

Authors:  Alan R Tall
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

3.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

4.  Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity.

Authors:  Serkan Torun; Bilge Demirel Tunc; Burak Suvak; Hakan Yildiz; Adnan Tas; Abdurrahim Sayilir; Yasemin Ozin Ozderin; Yavuz Beyazit; Ertugrul Kayacetin
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-07-27       Impact factor: 2.947

Review 5.  How neutrophils kill microbes.

Authors:  Anthony W Segal
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

6.  Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis.

Authors:  Basem Azab; Neil Jaglall; Jean Paul Atallah; Ari Lamet; Venkat Raja-Surya; Bachir Farah; Martin Lesser; Warren D Widmann
Journal:  Pancreatology       Date:  2011-09-28       Impact factor: 3.996

7.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

8.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

Authors:  D Gomez; S Farid; H Z Malik; A L Young; G J Toogood; J P A Lodge; K R Prasad
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

Review 9.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

Review 10.  Current and future diagnostic approaches: from serologies to imaging.

Authors:  David H Bruining; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2007-12
View more
  21 in total

1.  Neutrophil-to-Lymphocyte Ratio: An Easy Marker for the Diagnosis and Monitoring of Inflammatory Bowel Disease in Children.

Authors:  Pınar Şimşek-Onat; Hayriye Hizarcioglu-Gulsen; Yasin Maruf Ergen; Ersin Gumus; Hasan Özen; Hülya Demir; Seza Özen; İnci Nur Saltık-Temizel
Journal:  Dig Dis Sci       Date:  2022-05-17       Impact factor: 3.199

2.  The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease.

Authors:  Yi-Han Chen; Li Wang; Shu-Yi Feng; Wei-Min Cai; Xiao-Fu Chen; Zhi-Ming Huang
Journal:  Gastroenterol Res Pract       Date:  2020-06-22       Impact factor: 2.260

3.  Neutrophil-to-Lymphocyte Ratio, a Novel Inflammatory Marker, as a Predictor of Bipolar Type in Depressed Patients: A Quest for Biological Markers.

Authors:  Vlad Dionisie; Gabriela Adriana Filip; Mihnea Costin Manea; Robert Constantin Movileanu; Emanuel Moisa; Mirela Manea; Sorin Riga; Adela Magdalena Ciobanu
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

4.  Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.

Authors:  Shinya Takada; Hidetaka Murooka; Kanae Tahatsu; Maki Yanase; Kengo Umehara; Hirokazu Hashishita; Harabayashi Toru; Maruyama Satoru; Tamotsu Sagawa; Koshi Fujikawa; Hideki Sato; Kozo Mino
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

Review 5.  The Dual Role of Neutrophils in Inflammatory Bowel Diseases.

Authors:  Odile Wéra; Patrizio Lancellotti; Cécile Oury
Journal:  J Clin Med       Date:  2016-12-17       Impact factor: 4.241

6.  Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease.

Authors:  Jue-Rong Feng; Xiao Qiu; Fan Wang; Peng-Fei Chen; Qian Gao; Ya-Nan Peng; Xue Lin; Qing Liu; Jing Liu; Qiu Zhao; Jin Li
Journal:  Gastroenterol Res Pract       Date:  2017-07-17       Impact factor: 2.260

7.  Neutrophil-to-lymphocyte ratio shows faster changing kinetics than C-reactive protein after total hip and knee arthroplasty.

Authors:  Marcin Krzysztof Wasko; Marek Struminski; Konstancja Bobecka-Wesolowska; Jacek Kowalczewski
Journal:  J Orthop Translat       Date:  2017-06-01       Impact factor: 5.191

8.  Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu's arteritis: a case-control study.

Authors:  Lili Pan; Juan Du; Taotao Li; Hua Liao
Journal:  BMJ Open       Date:  2017-05-04       Impact factor: 2.692

9.  Prognostic value of preoperative neutrophil-to-lymphocyte ratio in Crohn's disease.

Authors:  Stanislaus Argeny; Anton Stift; Michael Bergmann; Martina Mittlböck; Svenja Maschke; Yushan Yang; Praminthra Chitsabesan; Stefan Riss
Journal:  Wien Klin Wochenschr       Date:  2018-02-12       Impact factor: 1.704

10.  Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation.

Authors:  Maki Komiyama; Yuka Ozaki; Yusuke Miyazaki; Yasufumi Katanasaka; Yoichi Sunagawa; Masafumi Funamoto; Kana Shimizu; Hajime Yamakage; Noriko Sato-Asahara; Akihiro Yasoda; Hiromichi Wada; Tatsuya Morimoto; Koji Hasegawa
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.